CARTITUDE-2: Can Earlier Cilta-Cel CAR-T Lead to Long-Term Remission or Cure in Myeloma? | IMS 2026

Niels van de Donk, MD, PhD, of Amsterdam UMC discusses long-term CARTITUDE-2 results for cilta-cel CAR-T at IMS 2026 in Glasgow. In patients with one to three prior lines of therapy, about half were alive and progression-free at five years, roughly double the one in three seen in more advanced disease. He explains why healthier T cells earlier in the disease may lead to longer remissions and how these results relate to the new definition of cure.


If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.